Breast Cancer
News
Ten-year data back shorter radiotherapy for breast cancer
Major Finding: The relapse rate at 10 years was 4.3% after the shorter 40 Gy regimen and 5.5% after the longer 50 Gy regimen, a nonsignificant...
Conference Coverage
HERA: Trastuzumab survival benefit strong at 8 years
Major Finding: At 8 years of follow-up, women who received 1 year of adjuvant trastuzumab had a 24% reduction in risk of all-cause mortality...
Conference Coverage
Bevacizumab misses - again - for breast cancer
Major Finding: Median 32-month rate of invasive disease-free survival was 85.5% with adjuvant chemotherapy plus a year of bevacizumab and 84.1%...
Video
Neoadjuvant chemo benefits young women with triple-negative breast cancer
Conference Coverage
Trastuzumab survival benefit still significant 10 years later
Major Finding: By year 10, 84% of those in treated with trastuzumab and paclitaxel were still alive vs. 75% of those given paclitaxel alone.Data...
Conference Coverage
Eribulin fails to best capecitabine in advanced breast cancer
Major Finding: Eribulin was not significantly better than capecitabine in median overall survival (15.9 vs. 14.5 months, P = .056) or progression-...
Video
ONC-CHAT: Dr. Martine Piccart, 'Absolutely No Advantage' to 2 Years of Trastuzumab
Conference Coverage
Studies put kibosh on statins for breast cancer prevention
News
Adjuvant Chemotherapy Boosts Survival in Locoregional Recurrent Breast Cancer
Major Finding: The 5-year disease-free survival rate after complete surgical removal of isolated local or regional recurrence of breast cancer was...